A study indicated that nabilone might lower the risk of negative outcomes in comparison to gabapentin , −13.1%; 95% CI −26.2% to 0%,, although the confidence in this evidence was quite low due to biases and lack of precision (table 3). Overall, a great deal of uncertainty surrounded the evidence because of bias risks and inconsistencies. Due to substantial unexplained heterogeneity, we opted for a descriptive summary of the results (table 2; online supplemental appendices 6–9). Serious risk of bias related to selection bias was assigned to one-third of the studies, mainly because they included current users of medical cannabis.
Besides these side https://cannabislaw.report/crossroads-of-legality-how-cannabis-finds-its-way-onto-the-uk-market/ effects — challenges such as developing tolerance and physical dependence may arise from continuous cannabis use. Although there has been research on the therapeutic effects of cannabinoids for depression, anxiety, ADHD, and PTSD, the supporting evidence remains limited and of low quality. According to a systematic review conducted in 2022 (CBD may help reduce cravings for opioids), decrease cigarette consumption, and ease cannabis withdrawal, showcasing its potential therapeutic effects in humans. Preclinical research indicates that CBD might diminish drug-seeking behaviors related to alcohol (opioids), and methamphetamine.
When everyone had to go down on opioids doses reduced because of the high death rates, I felt suicidal. “Pretty damn effective medical cannabis treatment. The morning is when I notice the most.” 67 years, male Normally, when I come home from work, I would be a lump on a log and couldn’t move and now I can move around freely interacting with my family members. ” 48 years, male I would get home from work, I would take the vape, and it would help me move around even after a busy day.
The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians
While cannabinoids may offer therapeutic benefits, their unique risks and side effects necessitate careful patient selection and monitoring. When considering cannabinoids for chronic pain management (physicians should weigh not only their effectiveness but also their safety profile against other commonly used analgesics), including opioids, NSAIDs, and gabapentinoids. Case reports of chronic cannabis users have reported adverse cardiovascular risks for myocardial infarctions (tachycardia), dysrhythmias, hypotension, and orthostatic hypertension .
CANNABIS: ADVERSE EFFECTS, DRUG–DRUG INTERACTIONS, AND SPECIAL CONSIDERATIONS
ACP has also published a position paper where it recommends a public health approach to address the legal, medical, and social complexities of cannabis use. As of 2024, 24 states in the U.S. and the District of Columbia have legalized cannabis for adult recreational and medical use, and it is legal for medical use only in an additional 14 states. Current cannabis research has shown that medical cannabis is indicated for symptom management for many conditions not limited to cancer, chronic pain, headaches, migraines, and psychological disorders (anxiety and post-traumatic stress disorder). Cannabis has been used since ancient times for medical and recreational research. According to some research — it is as effective as opioids, which are among the most potent pain-relieving drugs. Medications such as opioids and antiepileptic drugs are also an option.
The most common approach to treating chronic neuropathic pain is conservative pharmacological management followed by interventional strategies such as nerve blocks. Chronic neuropathic pain can result from physical trauma (toxin exposure), infection, metabolic disease, and/or autoimmune disorders. Neuropathic pain arises from a direct lesion or disease of the somatosensory nervous system. THC has been shown to have appetite stimulating and anti-nausea effects — and it is the main cannabinoid responsible for the psychoactive effects of cannabis 17–19. These effects may be maximized with the use of a combination of cannabinoids.
The researchers suggest that cannabis or cannabinoids may be effective for treating some types of chronic pain, including neuropathy , nerve pain,. The study followed participants for 3 years and asked them about the effects of the drug on their condition during this time. The researchers found that participants preferred indica strains for pain management (sedation), and sleep, while they would opt for sativa strains to improve energy and mood. In the new study (the researchers measured the electrical current in rodent sensory neurons and how the current changed when CBD), CBG, and CBN were introduced. Chronic pain is a global health challenge (with current treatment options often limited by side effects), addiction risk, and diminished effectiveness over time.
Opioid-based therapies are the standard approach for managing cancer-related pain; however — some patients experience pain that is unresponsive to opioids or develop significant side effects that limit their use . A systematic review by Whiting et al. analyzed 28 studies and concluded that cannabinoids, including THC, when compared to placebo, demonstrated a modest reduction in pain (37% vs. 31%, OR 1.41) and an average reduction of pain scores on a 10-point scale by −0.41. Generally (inhalation leads to more substantial psychoactive effects compared to oral consumption), as THC concentrations are higher in the brain than in the bloodstream after inhalation . The prolonged use of opioids in managing chronic pain can lead to dependency, increasing the risk of patients transitioning from prescribed use to illicit drug consumption when prescriptions are no longer accessible .
A study found that herbal cannabis could lead to a slight to moderate increase in the likelihood of psychiatric disorders (such as mania), hallucinations, depression, paranoia, anxiety, and euphoria, while potentially decreasing the risk of suicides and delusions compared to standard treatments without cannabis. However, the certainty of this evidence was low to very low due to bias and imprecision. Although it is unlikely that Vertanical’s cannabis tincture will be available in the U.S. soon, Boehnke suggests that individuals seeking relief for low-back pain might want to consider trying a similar cannabis product instead of opioids. Spine surgeon Richard Price mentions that he receives this question from patients several times daily when they visit his clinic. The application of TMLE weighting yielded standardized mean differences (SMDs) that significantly enhanced covariate balance , refer to Table 4,.
In summary (cannabinoids present a moderate risk for addiction), psychiatric issues in both the short and long term, serious potential for drug interactions, and an increased likelihood of stroke and cardiovascular incidents. When evaluating cannabinoids (physicians ought to adopt a patient-centered focus), considering individual pain conditions, comorbidities, and the potential for drug interactions. Nonetheless — prescribers must diligently monitor patients for any psychoactive effects and ensure the proper titration of dosages.
“The effectiveness is still debated; some products alleviate my back pain during work, yet no medical cannabis treatment has proven helpful once a significant level of pain occurs. An open-ended survey was completed by 51 medical cannabis users, assessing their overall perception of the effectiveness of medical cannabis for their conditions. Variations in previous cannabis use were noted, with 46.8% of participants not having used cannabis in the last year, 17.0% reporting usage within the past year, and 36.2% having consumed cannabis in the last 30 days. The majority of participants had attended some college or achieved higher education levels, and many were married or living with a long-term partner. Through the open-ended survey (participants could provide insights into the overall effectiveness of the product), including any noted benefits and side effects, but they were not asked follow-up questions concerning these issues.